📣 VC round data is live. Check it out!

ClearPoint Neuro Valuation Multiples

Discover ClearPoint Neuro's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like IVF hartmann, Universal Vision, TaiDoc Technology, Delcath Systems and more.

ClearPoint Neuro Overview

About ClearPoint Neuro

ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.


Founded

1998

HQ

United States

Employees

115

Financials (LTM)

Revenue: $44M
EBITDA: ($17M)

EV

$399M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

ClearPoint Neuro Financials

ClearPoint Neuro reported last 12-month revenue of $44M and negative EBITDA of ($17M).

In the same LTM period, ClearPoint Neuro generated $27M in gross profit, ($17M) in EBITDA losses, and had net loss of ($29M).

Revenue (LTM)


ClearPoint Neuro P&L

In the most recent fiscal year, ClearPoint Neuro reported revenue of $37M and EBITDA of ($15M).

ClearPoint Neuro is unprofitable as of last fiscal year, with gross margin of 61%, EBITDA margin of (41%), and net margin of (69%).

See analyst estimates for ClearPoint Neuro
LTMLast FY202320242025202620272028
Revenue$44M$37M$24M$31M$37M
Gross Profit$27M$23M$14M$19M$23M
Gross Margin61%61%57%61%61%
EBITDA($17M)($15M)($21M)($18M)($21M)
EBITDA Margin(40%)(41%)(88%)(57%)(56%)
EBIT Margin(60%)(65%)(94%)(63%)(65%)
Net Profit($29M)($26M)($22M)($19M)($26M)
Net Margin(66%)(69%)(92%)(60%)(69%)
Net Debt-$3M---

Financial data powered by Morningstar, Inc.

ClearPoint Neuro Stock Performance

ClearPoint Neuro has current market cap of $371M, and enterprise value of $399M.

Market Cap Evolution


ClearPoint Neuro's stock price is $12.37.

ClearPoint Neuro share price decreased by 2.4% in the last 30 days, and increased by 4.2% in the last year.

ClearPoint Neuro has an EPS (earnings per share) of $-0.85.

See more trading valuation data for ClearPoint Neuro
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$399M$371M-2.1%-2.4%37.4%4.2%$-0.85

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

ClearPoint Neuro Valuation Multiples

ClearPoint Neuro trades at 9.1x EV/Revenue multiple, and (23.0x) EV/EBITDA.

See NTM and 2027E valuation multiples for ClearPoint Neuro

EV / Revenue (LTM)


ClearPoint Neuro Financial Valuation Multiples

As of June 3, 2026, ClearPoint Neuro has market cap of $371M and EV of $399M.

ClearPoint Neuro has a P/E ratio of (12.9x).

LTMLast FY202320242025202620272028
EV/Revenue9.1x10.8x16.7x12.7x10.8x
EV/EBITDA(23.0x)(26.2x)(19.0x)(22.4x)(19.1x)
EV/EBIT(15.3x)(16.5x)(17.8x)(20.2x)(16.5x)
EV/Gross Profit14.8x17.6x29.3x20.9x17.6x
P/E(12.9x)(14.5x)(16.8x)(19.6x)(14.5x)
EV/FCF-(16.3x)(27.0x)(43.2x)(16.3x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified ClearPoint Neuro Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

ClearPoint Neuro Margins & Growth Rates

ClearPoint Neuro grew revenue by 44% and EBITDA by 33% in the last fiscal year.

In the most recent fiscal year, ClearPoint Neuro reported gross margin of 61%, EBITDA margin of (41%), and net margin of (69%).

See estimated margins and future growth rates for ClearPoint Neuro

ClearPoint Neuro Margins

Last FY202420252026202720282029
Gross Margin61%61%61%62%
EBITDA Margin(41%)(57%)(56%)(38%)
EBIT Margin(65%)(63%)(65%)(54%)
Net Margin(69%)(60%)(69%)(62%)
FCF Margin(66%)(29%)(66%)-

ClearPoint Neuro Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth44%31%18%44%
Gross Profit Growth44%40%19%44%
EBITDA Growth33%(15%)17%(3%)
EBIT Growth19%(12%)22%19%
Net Profit Growth29%(14%)35%29%
FCF Growth-(38%)165%-

Data powered by FactSet, Inc. and Morningstar, Inc.

ClearPoint Neuro Operational KPIs

ClearPoint Neuro's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.4M for the same period.

ClearPoint Neuro's Rule of 40 is 6% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ClearPoint Neuro's Rule of X is 71% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for ClearPoint Neuro
LTMLast FY202320242025202620272028
Rule of 40(8%)6%---
Bessemer Rule of X40%71%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.4M---
S&M Expenses to Revenue46%45%53%46%45%
G&A Expenses to Revenue41%45%49%38%45%
R&D Expenses to Revenue35%38%49%39%38%
Opex to Revenue-127%151%124%127%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

ClearPoint Neuro Competitors

ClearPoint Neuro competitors include IVF hartmann, Universal Vision, TaiDoc Technology, Delcath Systems, VieMed, Coltene, Senseonics Holdings, Orthofix Medical, CapsoVision and Advanced Technology Company.

Most ClearPoint Neuro public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
IVF hartmann1.1x-7.0x-
Universal Vision2.5x2.5x5.6x5.8x
TaiDoc Technology1.8x-4.1x-
Delcath Systems3.2x3.0x11.0x17.3x
VieMed1.4x1.3x6.0x5.7x
Coltene1.3x1.4x11.4x11.1x
Senseonics Holdings9.5x7.2x(5.4x)-
Orthofix Medical0.7x0.6x6.4x6.2x

This data is available for Pro users. Sign up to see all ClearPoint Neuro competitors and their valuation data.

Start Free Trial

Acquisitions by ClearPoint Neuro

ClearPoint Neuro has acquired 1 company to date.

Last acquisition by ClearPoint Neuro was on November 6th 2025. ClearPoint Neuro acquired Irras for $28M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by ClearPoint Neuro

Irras
Description
Irras is a Stockholm-based medical technology company offering IRRAflow systems for intracranial fluid management in neurosurgery. The platform enables irrigation, aspiration, fluid infusion, and pressure monitoring for brain pathologies like edema and hemorrhage.
HQ CountryUnited States
HQ City
San Diego, CA
Deal Date6 Nov 2025
Valuation$28M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all ClearPoint Neuro acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About ClearPoint Neuro

When was ClearPoint Neuro founded?ClearPoint Neuro was founded in 1998.
Where is ClearPoint Neuro headquartered?ClearPoint Neuro is headquartered in United States.
How many employees does ClearPoint Neuro have?As of today, ClearPoint Neuro has over 115 employees.
Who is the CEO of ClearPoint Neuro?ClearPoint Neuro's CEO is Joseph M. Burnett.
Is ClearPoint Neuro publicly listed?Yes, ClearPoint Neuro is a public company listed on Nasdaq.
What is the stock symbol of ClearPoint Neuro?ClearPoint Neuro trades under CLPT ticker.
When did ClearPoint Neuro go public?ClearPoint Neuro went public in 2012.
Who are competitors of ClearPoint Neuro?ClearPoint Neuro main competitors include IVF hartmann, Universal Vision, TaiDoc Technology, Delcath Systems, VieMed, Coltene, Senseonics Holdings, Orthofix Medical, CapsoVision, Advanced Technology Company.
What is the current market cap of ClearPoint Neuro?ClearPoint Neuro's current market cap is $371M.
What is the current revenue of ClearPoint Neuro?ClearPoint Neuro's last 12 months revenue is $44M.
What is the current revenue growth of ClearPoint Neuro?ClearPoint Neuro revenue growth (NTM/LTM) is 32%.
What is the current EV/Revenue multiple of ClearPoint Neuro?Current revenue multiple of ClearPoint Neuro is 9.1x.
Is ClearPoint Neuro profitable?No, ClearPoint Neuro is not profitable.
What is the current EBITDA of ClearPoint Neuro?ClearPoint Neuro has negative EBITDA and is not profitable.
What is ClearPoint Neuro's EBITDA margin?ClearPoint Neuro's last 12 months EBITDA margin is (40%).
What is the current EV/EBITDA multiple of ClearPoint Neuro?Current EBITDA multiple of ClearPoint Neuro is (23.0x).
How many companies ClearPoint Neuro has acquired to date?As of June 2026, ClearPoint Neuro has acquired 1 company.
What was the largest acquisition by ClearPoint Neuro?$28M acquisition of Irras on 6th November 2025 was the largest M&A ClearPoint Neuro has done to date.
What companies ClearPoint Neuro acquired?ClearPoint Neuro acquired Irras.
In how many companies ClearPoint Neuro has invested to date?ClearPoint Neuro hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to ClearPoint Neuro

Lists including ClearPoint Neuro

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial